ESPERION THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.25 USD | -5.46% |
|
-13.13% | -24.75% |
Presenter SpeechJason Zemansky (Analysts)My name is Jason Zemansky. I'm one of the new SMID-ca...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.
Sector
Pharmaceuticals
Calendar
08:00am
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.38
USD
Average target price
7.414
USD
Spread / Average Target
+211.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.75% | 451M | |
| +38.69% | 723B | |
| +34.28% | 595B | |
| -4.49% | 369B | |
| +20.24% | 332B | |
| +2.12% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -5.07% | 205B | |
| -0.35% | 168B |
- Stock Market
- Equities
- ESPR Stock
- News Esperion Therapeutics, Inc.
- Transcript : Esperion Therapeutics, Inc. Presents at Bank of America Securities 2023 Healthcare Conference, May-11-2023 08
